Big Pharma pursues epigenetics for cancer breakthroughs

Big Pharma companies like GlaxoSmithKline, Eli Lilly and Novartis are among the drugmakers pursuing new cancer treatments based on epigenetics--an approach that aims to reprogram abnormal DNA that causes cells to become cancerous. Epigenetics is already used in oncology drugs that treat certain blood-cancer disorders, but the real test will be to see whether it can also be applied to solid tumor cancers. Piece

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.